{'fraction_non_alphanumeric': 0.04373927958833619, 'fraction_numerical': 0.009433962264150943, 'mean_word_length': 5.668571428571428, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Co‐delivery of platelet‐derived growth factor (PDGF‐BB) and bone morphogenic protein (BMP‐2) coated onto heparinized titanium for improving osteoblast function and osteointegration

The aim of this study was to improve osteoblast function by delivering two growth factors, PDGF‐BB and BMP‐2, incorporated onto heparinized titanium (Hep‐Ti) substrate. To achieve co‐delivery of PDGF‐BB and BMP‐2, the surface of anodized Ti was immobilized with heparin, and then the two growth factors were coated onto the Hep‐Ti surface. Incorporation of the two growth factors onto Hep‐Ti was evaluated by SEM and XPS. Incorporated PDGF‐BB and BMP‐2 were released from the Hep‐Ti substrate in a sustained manner. In vitro studies revealed that osteoblasts grown on PDGF‐BB‐ and BMP‐2‐immobilized Hep‐Ti increased ALP activity, calcium deposition, osteocalcin and osteopontin levels as compared to those grown on PDGF‐BB alone‐ or BMP‐2 alone‐immobilized Hep‐Ti. These results suggested that co‐delivery of PDGF‐BB and BMP‐2 using Hep‐Ti substrate will be a promising material for the enhancement of osteoblast function and osteointegration. Copyright © 2013 John Wiley & Sons, Ltd.